Shopping Cart
- Remove All
- Your shopping cart is currently empty
Tifcemalimab (JS004), a humanized monoclonal antibody targeting BTLA (B and T lymphocyte attenuation factor), inhibits the HVEM-BTLA interaction by binding to BTLA. This action prevents the BTLA-mediated inhibitory signaling pathway, making Tifcemalimab a potential tool in cancer research [1].
Pack Size | Price | Availability | Quantity |
---|---|---|---|
5 mg | Inquiry | Backorder |
Description | Tifcemalimab (JS004), a humanized monoclonal antibody targeting BTLA (B and T lymphocyte attenuation factor), inhibits the HVEM-BTLA interaction by binding to BTLA. This action prevents the BTLA-mediated inhibitory signaling pathway, making Tifcemalimab a potential tool in cancer research [1]. |
Storage | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.